Parkinson’s Disease Weight Loss Linked to Metabolic Shift, Not Muscle Loss, New Study Reveals
A groundbreaking new study published November 30, 2025, challenges long-held assumptions about weight loss in Parkinson’s disease (PD), revealing it’s driven by a fundamental shift in how the body produces energy – specifically, a selective loss of body fat – rather than simply reduced food intake or muscle wasting.
For years, unexplained weight loss has been a recognized, yet poorly understood, non-motor symptom of PD, often worsening alongside motor impairments and diminished quality of life. Until now, the underlying cause remained elusive.
Researchers at Fujita Health University in Japan, led by Professor Hirohisa Watanabe, sought to pinpoint exactly what is lost when PD patients lose weight and why their bodies alter their energy strategy. The team enrolled 91 individuals with PD and 47 healthy controls, conducting detailed body composition analyses using bioelectrical impedance analysis to measure fat mass, muscle mass, and other components. Simultaneously, they performed plasma metabolomic profiling via mass spectrometry to assess key metabolic pathways, including glycolysis, the Krebs cycle, lipid metabolism, mitochondrial function, and ketone body production.
The results painted a striking picture. Compared to the control group, PD patients exhibited lower body weight and body mass index, almost entirely attributable to a reduction in body fat. “We clarified that it is not the muscle that is decreasing, but the fat,” stated Professor Watanabe. “This changes how we should think about weight loss in Parkinson’s disease.” Muscle mass remained largely preserved in the early to mid-stages of the disease, with rates of sarcopenia – age-related muscle loss – comparable to the general population.
The study revealed that this fat loss isn’t an isolated phenomenon, but a consequence of a deeper metabolic failure. Researchers found significantly reduced levels of key metabolites like lactic acid and succinic acid, indicating impaired glycolysis and dysfunction of the TCA cycle – the body’s primary energy production system. This impairment prevents glucose from being efficiently converted into usable energy.
As a result, the body activates a survival mechanism, shifting to an “emergency engine” fueled by fat and protein breakdown. Markers of ketone bodies, such as acetoacetic acid, were elevated, alongside metabolites associated with amino acid catabolism. In essence, when carbohydrate metabolism falters, the body is forced to burn fat to survive.
This metabolic shift wasn’t uniform across all patients. Ketone body levels were highest in those who were thinner and had more advanced disease, suggesting a progressive reliance on fat breakdown as PD progresses. “Being thin may signal an invisible energy crisis occurring inside the patient’s body,” explained Dr. Atsuhiro Higashi. “The body is forced to burn fat to survive.” .
The findings have significant implications for future care. Simply increasing calorie intake may prove ineffective if the body’s primary energy engine is compromised. The research suggests a need to re-evaluate nutritional and therapeutic strategies for PD, potentially exploring interventions that stabilize glycolysis, improve mitochondrial function, or prevent excessive ketone body production – approaches distinct from traditional dopamine replacement therapy.
The study underscores that Parkinson’s disease is not solely a neurological disorder, but a systemic condition driven by hidden metabolic dysfunction. By demonstrating that weight loss stems from selective fat depletion due to impaired carbohydrate-based energy production, not muscle loss, the research provides a new framework for identifying at-risk patients and intervening earlier. Recognizing “thinness” as a biological warning sign could enable more proactive, personalized care to prevent disease-related energy collapse.
Source: Higashi, A., et al. (2025). Metabolic profiles associated with fat loss in Parkinson’s disease. Journal of Neurology, Neurosurgery & Psychiatry. DOI: 10.1136/jnnp-2025-336929. https://jnnp.bmj.com/content/early/2025/11/30/jnnp-2025-336929
